➤ Topline results for investigational diabetic retinopathy therapy ➤ Dosing complete in second cohort for Phase 1/2 trial for geographic atrophy therapy ➤ Large data modules launched for dry eye disease and thyroid eye disease ➤ Study: Real-world outcomes of MIGS combined with cataract surgery vs. cataract surgery alone ➤ ASCRS news and events
➤ Enrollment complete in MIGS pivotal trial ➤ Acquisition of dry eye drop ➤ Two-year results post-cilio-scleral glaucoma procedure ➤ Positive topline results from Phase 2 study of retinitis pigmentosa treatment ➤ ASCRS news and events
➤ ASCRS EyeWorld Weekly: View the current issue ➤ Allogenic cell therapy receives regulatory approval for bullous keratopathy indication ➤ 24-month data on AMD photobiomodulation therapy ➤ Patient enrollment complete for Phase 3 trial evaluating topical presbyopia treatment ➤ Pre-IND meeting for treatment of corneal endothelial disease ➤ IND submitted for geographic atrophy treatment ➤ Second Phase 3 trial for dry eye disease therapy ➤ ASCRS news and events
➤ Results from investigational non-incisional glaucoma treatment ➤ Study: preservative-free latanoprost efficacy similar to preserved alternative ➤ FDA accepts priority review NDA for vitreoretinal lymphoma treatment ➤ Companies partner to develop dry eye drop ➤ Company announces lead asset in its agonist antibody pipeline ➤ ASCRS news and events
➤ FDA accepts NDA for dry eye treatment ➤ Phase 2 study moves forward for investigational ocular autoimmune therapy ➤ Fast-track designation granted for investigational retinitis pigmentosa treatment ➤ First-in-human feasibility study data from drug-eluting IOL platform ➤ Study identifies the ‘best approach’ for anti-VEGF therapy for diabetic retinopathy ➤ ASCRS news and events
➤ FDA accepts NDA for pupil dilation spray ➤ NDA for new glaucoma drug accepted ➤ PMA application submitted to FDA for new IOL ➤ Data report: 12-month efficacy seen from single mechanical MGD treatment ➤ Acquisition of company developing drugs for rare ophthalmic diseases ➤ ASCRS news and events
➤ NDA submitted for new, topical dry eye disease treatment ➤ IND submitted for persistent corneal epithelial defect treatment ➤ IND filed for dry eye disease treatment ➤ Study: Investigational topical drop reduces inflammation in anterior uveitis cases ➤ Alcon completes acquisition of Aerie ➤ ASCRS news and events
➤ Phase 1/2a results for suprachoroidal wet AMD treatment ➤ Enrollment complete for two Phase 2 trials investigating dry eye therapies disease ➤ Phase 2b study for drug-eluting contact lens begins ➤ Healthcare company acquires biopharmaceutical company developing ophthalmic treatments ➤ Development and commercialization licensing agreement ➤ ASOA podcast features dry eye info for the practice ➤ ASCRS news and events
➤ FDA clearance for viscodelivery system ➤ FDA approves IND application for immunomodulatory agent for dry eye ➤ Phase 2b results for sustained-release, IOP-lowering implant ➤ Positive topline Phase 2 results for investigational dry eye drug ➤ Phase 2 trials begin for two transdermal drug formulations ➤ Second pivotal trial begins for wet AMD gene therapy ➤ Alcon completes acquisition of Ivantis ➤ ASCRS news and events